Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PRIMO 2025 | AI in cancer research: advancing clinical trials & real-world data analysis

Merrick Ross • 7 Feb 2025
PRIMO 2025
General

Merrick Ross, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential benefits of artificial intelligence in cancer research, highlighting its potential to aid in designing clinical trials and analyzing real-world data to inform decision-making. Dr Ross notes that the past decade has seen significant advancements, and he anticipates even more remarkable progress in the next decade. This interview took place at the PRIMO 2025 congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Merrick Ross

mRNA vaccines in melanoma: targeting neoantigens to enhance immunotherapy & reduce toxicity
4:37
mRNA vaccines in melanoma: targeting neoantigens to enhance immunotherapy & reduce toxicity
Merrick Ross • 7 Feb 2025
Optimizing immunotherapy: predictive biomarkers, resistance strategies & personalized medicine
3:37
Optimizing immunotherapy: predictive biomarkers, resistance strategies & personalized medicine
Merrick Ross • 7 Feb 2025
Predictive biomarkers & neoadjuvant platforms in cancer treatment personalization
3:33
Predictive biomarkers & neoadjuvant platforms in cancer treatment personalization
Merrick Ross • 7 Feb 2025
Anti-LAG-3 and anti-PD-1 combination shows promising results in advanced melanoma treatment
1:07
Anti-LAG-3 and anti-PD-1 combination shows promising results in advanced melanoma treatment
Merrick Ross • 7 Feb 2025

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals